# [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

> **NCT06229366** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 142 (estimated)

## Conditions studied

- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Oligometastatic Prostate Carcinoma
- Hormone Sensitive Prostate Cancer

## Interventions

- **DRUG:** [Ac-225]-PSMA-62 (mCRPC)
- **DRUG:** [Ac-225]-PSMA-62 (OmHSPC)

## Key facts

- **NCT ID:** NCT06229366
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-03
- **Primary completion:** 2027-09
- **Final completion:** 2032-12
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06229366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06229366, "[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06229366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*